Showing results (441-450 of 2,034) with videos related to
Sort By:
Pageof 204
The Journal of Pharmacology and Experimental Therapeutics|July 15, 2005
The metabotropic glutamate 5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine reduces ethanol self-administration in multiple strains of alcohol-preferring rats and regulates olfactory glutamatergic systemsMichael S Cowen, Elvan Djouma, Andrew J LawrencePsychopharmacology|November 11, 2006
Assessing appetitive and consummatory phases of ethanol self-administration in C57BL/6J mice under operant conditions: regulation by mGlu5 receptor antagonismMichael S Cowen, Elena Krstew, Andrew J LawrenceThe Journal of Biological Chemistry|October 30, 2008
Animal models of polyglutamine diseases and therapeutic approachesJ Lawrence Marsh, Tamas Lukacsovich, Leslie Michels ThompsonBiotechnology and Bioengineering|May 8, 2009
Modeling nutrient consumptions in large flow-through bioreactors for tissue engineeringMamatha Devarapalli, Benjamin J Lawrence, Sundararajan V MadihallyPediatric Nephrology (Berlin, Germany)|September 28, 2011
Newborn screening and renal disease: where we have been; where we are now; where we are goingJ Lawrence Merritt, David Askenazi, Si Houn HahnJournal of the Autonomic Nervous System|February 5, 1996
Radioligand binding and autoradiographic visualization of adenosine transport sites in human inferior vagal ganglia and their axonal transport along rat vagal afferent neuronsM Castillo-Meléndez, B Jarrott, A J LawrenceJournal of Post Anesthesia Nursing|August 1, 1990
An adaptation of the Miller patient classification system for the postanesthesia care unit at Children's Hospital of Eastern OntarioJ Kay, D Alcock, J Lawrence, et al.The American Journal of Psychiatry|September 1, 1983
Platelet MAO activity and the dexamethasone suppression test in depressed patientsA F Schatzberg, P J Orsulak, A J Rothschild, et al.Psychopharmacology|January 1, 1981
Toward a biochemical classification of depressive disorders. III: Pretreatment urinary MHPG levels as predictors of response to treatment with maprotilineA F Schatzberg, A H Rosenbaum, P J Orsulak, et al.The Journal of Clinical Psychiatry|October 11, 1991
Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophreniaS L McElroy, E C Dessain, H G Pope, et al.Pageof 204